Treatments

*September 2021* Note  MET can be a resistance mechanism to Tagrisso In this video, Dr Felip discusses the most recent efficacy data from ASCO 2021 on the use of MET inhibitors in NSCLC. View the video here. In this interview Dr Felip answers the following questions: How significant is MET as a therapeutic target…

*September 2021* From Blueprint Medicines:  Currently, there are no approved therapies for patients with osimertinib-resistant EGFRm NSCLC, and there is an urgent need for new therapies to address tumor resistance. BLU-945 was designed to potently inhibit triple-mutant EGFR harboring either the activating L858R or exon 19 deletion mutations combined with…

*August 2021* A discussion on how this variant of NSCLC differs from the (exon 19 and exon 21) EGFR mutations and the demographics of EGFR patients. View the entire transcript or watch the video here. Alexander I. Spira, MD, PhD, FACP: I know we talked a little bit about this before,…

*August 2021* There have been many discussions in our EGFR Resisters Facebook group regarding the use of immunotherapy in EGFR+ lung cancer. Three lung cancer doctors weigh in: Read more. And here is Dr. Ross Camidge on the topic: Read more.

*August 2021* In this video, Dr. David Carbone talked about the promise and successes of targeted therapies and immunotherapy, answered questions about oncogene mutations and available treatments, and outlined current studies that could be game-changers for lung cancer patients. Watch the video here.

*August 2021* Introduction Management of central nervous system (CNS) metastases in patients with driver-mutated NSCLC has traditionally incorporated both tyrosine kinase inhibitors (TKIs) and intracranial radiation. Whether next generation, CNS-penetrant TKIs can be used alone without upfront radiation, however, remains unknown. This multi-institutional retrospective analysis aimed to compare outcomes in…

*July 2021* Note: Although the use of immunotherapy can be questionable in EGFR+ lung cancer, resistance to immunotherapy might be of interest anyway. Non-small cell lung cancer (NSCLC) is the most common form of lung cancer and is usually not diagnosed until an advanced-stage disease is present. Chemotherapy is the…

*May 2021* Note: Is further evaluation of the combination warranted for patients with locally advanced or metastatic T790M-negative, EGFR-positive NSCLC? The combination of oleclumab (MEDI9447) and osimertinib (Tagrisso) was well-tolerated and demonstrated preliminary anti-tumor activity in patients with non-small-cell lung cancer (NSCLC) with an epidermal growth factor receptor mutation (EFGR) mutation…

*July 2021* Note  Should a VEGF inhibitor (bevacizumab/Avastin) be combined with osimertinib or not? The role of osimertinib combinations as second-line treatment for advanced non-small cell lung cancer (NSCLC) is still unclear, according to researchers. Osimertinib is a standard first-line treatment option for patients with advanced NSCLC and EGFR mutations, but progression on this…

*July 2021* Patritumab deruxtecan (HER3-DXd), an antibody drug conjugate consisting of a fully human monoclonal antibody to HER3 attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker, achieved clinically meaningful, durable efficacy in a phase I dose escalation and dose expansion study conducted in patients with locally…